Key result
COMP-Ang-1 treatment significantly improved cardiac function after myocardial ischemia/reperfusion injury, resulting in a higher ejection fraction of 48.05% compared to 31.4% in the control group.
Why the study?
Does angiopoietin-1 improve cardiac function and reduce vascular leakage and cardiomyocyte death in ischemia/reperfusion injury models?
Does angiopoietin-1 improve cardiac function and reduce vascular leakage and cardiomyocyte death in ischemia/reperfusion injury models?
Absolute Event Rate: 48.05% vs 31.4%
p-value: p=<0.05
Angiopoietin-1 protects against myocardial ischemia/reperfusion injury by reducing vascular leakage via VE-cadherin dephosphorylation and preventing cardiomyocyte apoptosis via the integrin-β1/ERK/caspase-9 pathway.
No takes yet. Share an insight, caveat, or question.
COMP-Ang-1 may aid post-I/R recovery in animals; leaves open human translation and trials.
Lee et al. (2011) studied Myocardial ischemia/reperfusion injury. COMP-Ang-1 (cAng-1) vs. Ad-β-gal was evaluated on Ejection fraction at 4 weeks (p=<0.05). COMP-Ang-1 treatment significantly improved cardiac function after myocardial ischemia/reperfusion injury, resulting in a higher ejection fraction of 48.05% compared to 31.4% in the control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: